Ansbert Gadicke bought $20M of AKTS
owner at Aktis Oncology, Inc.. 1,112,777 shares at an average of $18.00, traded Jan 12, 2026, filed Jan 14, 2026.
Score components
- +12Role10% owner
- +25Trade size$20.0M at market
- +3Relative to holdingsHoldings up 12%
- +10Price context0% above the 52-week low
- +15Cluster6 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -14.7%, 3m -13.1%, 6m +24.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-26-000055, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 12, 2026 | CConversion Common Stockindirect: See Footnote | +1,314,262 | - | - | 1,655,971 | Jan 14, 2026 |
| Jan 12, 2026 | CConversion Common Stockindirect: See Footnote | +5,914,197 | - | - | 7,570,168 | Jan 14, 2026 |
| Jan 12, 2026 | CConversion Common Stockindirect: See Footnote | +1,577,119 | - | - | 9,147,287 | Jan 14, 2026 |
| Jan 12, 2026 | POpen-market purchase Common Stockindirect: See Footnote | +1,112,777 | $18.00 | $20M | 10,260,064 | Jan 14, 2026 |
| Jan 12, 2026 | CConversion Series Seed Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -5,000,000 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 12, 2026 | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -22,500,000 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 12, 2026 | CConversion Series B Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -6,000,000 | $0.00 | $0 | 0 | Jan 14, 2026 |
Related signals
Other insiders at Aktis Oncology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | Aktis Oncology, Inc. | Akos Czibere Chief Medical Officer | $259k 12,500 shares | -100% | |
| 45Moderate | Aktis Oncology, Inc. | Ken Herrmann director | $119k 4,856 shares | -100% | |
| 43Moderate | Aktis Oncology, Inc. | Ken Herrmann director | $77k 3,065 shares | -100% | |
| 60Notable | Aktis Oncology, Inc. | Akos Czibere Chief Medical Officer | $1.4M 50,000 shares | -100% | |
| 65Notable | Aktis Oncology, Inc. | Shulamit Ron-Bigger Chief Operating Officer | $1.4M 50,000 shares | -100% | |
| 60Notable | Aktis Oncology, Inc. | Mpm Bioventures 2018, L.p. owner | $20M 1,112,777 shares | +12% | |
| 68Notable | Aktis Oncology, Inc. | Todd Foley director, owner | $4.2M 232,870 shares | +6% | |
| 75Notable | Aktis Oncology, Inc. | EcoR1 Capital, LLC director | $40M 2,222,222 shares | +98% | |
| 68Notable | Aktis Oncology, Inc. | Helen Susan Kim director, owner | $15M 835,000 shares | +17% | |
| 60Notable | Aktis Oncology, Inc. | Vida Ventures II, LLC owner | $15M 835,000 shares | +17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.